1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Shire receives additional Vyvanse patent challenges

 
• By Nancy Faigen

Two other generics firms – Amneal Pharmaceuticals and Watson Laboratories - have filed ANDAs with the US FDA for generic versions of Shire Pharmaceuticals’ top-selling drug for attention deficit hyperactivity disorder (ADHD) product, Vyvanse (lisdexamfetamine dimesylate), challenging the listed patents.

Two other generics firms – Amneal Pharmaceuticals and Watson Laboratories - have filed ANDAs with the US FDA for generic versions of Shire Pharmaceuticals’ top-selling drug for attention deficit hyperactivity disorder (ADHD) product, Vyvanse (lisdexamfetamine dimesylate), challenging the listed patents.

These are the second and third notices the company has received concerning ANDA submissions that contain a challenge to all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapeutic Category

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.